Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 1
1976 1
1991 1
1996 2
1997 2
1998 3
1999 2
2001 2
2002 4
2003 4
2004 1
2005 9
2006 8
2007 16
2008 11
2009 17
2010 30
2011 25
2012 22
2013 18
2014 18
2015 22
2016 23
2017 17
2018 13
2019 22
2020 15
2021 15
2022 6
2023 4
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

280 results

Results by year

Filters applied: . Clear all
Page 1
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, Tsurutani J, Ueno NT, Prat A, Chae YS, Lee KS, Niikura N, Park YH, Xu B, Wang X, Gil-Gil M, Li W, Pierga JY, Im SA, Moore HCF, Rugo HS, Yerushalmi R, Zagouri F, Gombos A, Kim SB, Liu Q, Luo T, Saura C, Schmid P, Sun T, Gambhire D, Yung L, Wang Y, Singh J, Vitazka P, Meinhardt G, Harbeck N, Cameron DA; DESTINY-Breast04 Trial Investigators. Modi S, et al. Among authors: chae ys. N Engl J Med. 2022 Jul 7;387(1):9-20. doi: 10.1056/NEJMoa2203690. Epub 2022 Jun 5. N Engl J Med. 2022. PMID: 35665782 Free PMC article. Clinical Trial.
Cardiac Safety and Efficacy of SB3 Trastuzumab Biosimilar for ERBB2-Positive Early Breast Cancer: Secondary Analysis of a Randomized Clinical Trial.
Pivot X, Cortés J, Lüftner D, Lyman GH, Curigliano G, Bondarenko IM, Ahn JH, Im SA, Litwiniuk M, Shparyk YV, Ho GF, Kislov NV, Wojtukiewicz M, Sarosiek T, Chae YS, Ahn JS, Jang H, Kim S, Lee J, Yoon Y. Pivot X, et al. Among authors: chae ys. JAMA Netw Open. 2023 Apr 3;6(4):e235822. doi: 10.1001/jamanetworkopen.2023.5822. JAMA Netw Open. 2023. PMID: 37022687 Free PMC article. Clinical Trial.
A phase Ia/Ib study of novel anti-ErbB3 monoclonal antibody, barecetamab (ISU104) in refractory solid cancers and monotherapy or in combination with cetuximab in recurrent or metastatic head and neck cancer.
Seo S, Keam B, Shin SH, Chae YS, Kim TM, Park LC, Hong SB, Ahn MJ, Kim SB. Seo S, et al. Among authors: chae ys. Int J Cancer. 2023 Oct 15;153(8):1501-1511. doi: 10.1002/ijc.34622. Epub 2023 Jun 26. Int J Cancer. 2023. PMID: 37357950 Clinical Trial.
Hyalinizing Cholecystitis and Associated Carcinoma: A Case Report.
Kang Y, Chae YS, Kim CH, Lee Y, Kim DS, Yu YD, Kim JY. Kang Y, et al. Among authors: chae ys. J Pathol Transl Med. 2018 Jan;52(1):64-66. doi: 10.4132/jptm.2016.11.04. Epub 2017 Apr 4. J Pathol Transl Med. 2018. PMID: 28372345 Free PMC article. No abstract available.
280 results